Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Allakos IncALLK-0.550.000.95-0.24-121.68%-65.53%49.03$1.00$2.795,084$1.11

Detail of Allakos Inc

 
CEO
Dr. Robert Alexander Ph.D.
Employees
192
Industry
Biotechnology
Sector
Healthcare
Market cap
$98M

Company details

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Allakos Inc
ALLK • XNGS • US
$1.11
-1.73 (-60.70%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.02
Margin profit
0.00%
52 week low
$0.54
52 week high
$3.23
50-day simple moving average
$1.03
200-day simple moving average
$1.00
Percent held by insiders
2.32%
Percent held by institutions
81.63%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ALLK -62.67%
eps change
ALLK 0.00%